Spyre Therapeutics initiated at Overweight by JP Morgan
JP Morgan initiated coverage of Spyre Therapeutics with an Overweight rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.